Refining And Testing A Promising New Treatment For Chronic Pain.
Funder
National Health and Medical Research Council
Funding Amount
$743,947.00
Summary
Chronic pain costs Australia about 35 billion dollars a year. Recent scientific discoveries show that treatment aimed at correcting problems in how the brain processes sensory input can reduce pain and disability. This project will clarify some key aspects of these problems and use that information to make final adjustments to an already very promising treatment. We will then test the treatment in a definitive and comprehensive clinical trial.
Reduction Of Chronic Post-surgical Pain With Ketamine - ROCKet Study
Funder
National Health and Medical Research Council
Funding Amount
$4,823,395.00
Summary
Chronic post-surgical pain (CPSP) is a common complication of major surgery, and a significant burden on quality of life and ongoing health costs. Ketamine is a drug used by anaesthetists to treat severe acute surgical pain. Various small studies suggest that it may be unique in its ability to reduce the risk of CPSP. We propose a large trial of ketamine during & after anaesthesia for major surgery to test this. Demonstration of effectiveness would promote widespread change in clinical practice.
Irritable Bowel Syndrome (IBS) is one of the leading causes of chronic pain both world-wide and in Australia for which there is a lack of treatments. Chronic pain arises from nerve fibres in the colon wall, which fail to 'reset' back to normal following inflammation. Targeting these nerve endings with drugs is a key advance in IBS treatment. This project will identify selective oxytocin analogues that act in the colon to lower pain in sensory nerves thus providing efficacious pain relief in IBS.
Understanding Persistent Low Back Pain Where It Resides, In The Brain
Funder
National Health and Medical Research Council
Funding Amount
$848,972.00
Summary
Low back pain is a leading cause of disability amongst Australians. A critical question is why some people get better after hurting their back while others do not. This project examines whether changes in the brain predict low back pain outcome. This information will rapidly advance our understanding of low back pain and has the potential to facilitate the development of novel therapies.
Neuropathic pain is particularly difficult to treat and existing medications have considerable side effects. This project will develop a new set of glycine transport inhibitors that have the potential to provide pain relief without side effects.
The First Placebo-controlled Trial Of Opioid Analgesics For Acute Spinal Pain
Funder
National Health and Medical Research Council
Funding Amount
$1,024,067.00
Summary
Despite the widespread and increasing use of opioid analgesics, there is a complete lack of evidence on their efficacy in acute spinal pain. Concerns are also being raised because of the risks of potentially serious adverse events associated with opioid analgesics. In this world-first study, we will establish whether using opioid analgesics can effective reduce pain in people with acute spinal pain and provide rigorous evidence to inform the safe and appropriate use of this medicine.
Resolve: A New Treatment - Sensorimotor Retaining With Explaining Pain - For Chronic Low Back Pain.
Funder
National Health and Medical Research Council
Funding Amount
$1,005,534.00
Summary
Most treatments for low back pain that are provided by a GP, physiotherapist or chiropractor are only moderately effective. A new approach is needed. We have developed a new treatment, sensorimotor retraining, based on principles from neuroscience, education, psychology and physiotherapy that we are testing in a randomized controlled trial. If successful this new treatment will provide relief for the millions of Australians who suffer from this debilitating condition.
Molecular Targets Of Amino Acid/neurotransmitter Conjugates Of Fatty Acids
Funder
National Health and Medical Research Council
Funding Amount
$846,390.00
Summary
This project investigates endogenous chemicals that affect cells important for detecting and responding to pain. We aim to discover how these compounds affect proteins important for nerve cell function, particularly proteins that have a prominent role in detecting and transmitting painful events. The compounds we examine are not themselves likely to be drugs, but future therapies may involve manipulating the levels of these chemicals in the body, or using drugs that mimic the activity of these c ....This project investigates endogenous chemicals that affect cells important for detecting and responding to pain. We aim to discover how these compounds affect proteins important for nerve cell function, particularly proteins that have a prominent role in detecting and transmitting painful events. The compounds we examine are not themselves likely to be drugs, but future therapies may involve manipulating the levels of these chemicals in the body, or using drugs that mimic the activity of these compounds.Read moreRead less
Pregabalin In Addition To Usual Care For Sciatica (PRECISE): A Randomised, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$638,663.00
Summary
Sciatica is a severe and disabling form of back pain that is characterised by radiating pain down the leg. However there is little evidence on how best to treat it conservatively. We propose to investigate the effectiveness of pregabalin, a medication that specifically targets sciatic pain, in addition to usual care in 204 patients with sciatica. We hypothesise that adding pregabalin will be more effective in reducing the severity of leg pain.
Spinal Cord Injury Pain: Understanding Mechanisms To Develop Treatments
Funder
National Health and Medical Research Council
Funding Amount
$597,675.00
Summary
Spinal cord injury has devastating effects on health and quality of life. Many of the major consequences of injury, such as chronic pain and loss of voluntary voiding, are "invisible" – i.e., they are not as visible as limitations of mobility. Our study aims to define the neurobiological changes that cause development of persistent pain after spinal cord injury and use pharmacological tools to attenuate the development of pain.